This article was originally published in SRA
Postmarketing studies becoming routine in the US, Europe and Japan
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.